Fate of Myeloma Drug’s Comeback Now Rests in Hands of FDA Panel

(MedPage Today) — FDA staff noted that the benefit-risk profile of belantamab mafodotin (Blenrep) in relapsed and refractory multiple myeloma remains murky given its checkered history in a briefing document released ahead of a meeting of the agency…